Page last updated: 2024-10-27

glimepiride and Obesity

glimepiride has been researched along with Obesity in 14 studies

glimepiride: structure given in first source

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)."5.48Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018)
"Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes."5.39The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013)
"To assess the pharmacokinetic characteristics of glimepiride and its metabolites in normal-weight and morbidly obese patients with type 2 diabetes to determine whether the pharmacokinetics of glimepiride are altered by obesity."5.11Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. ( Chi, EM; Lehr, KH; Shukla, UA, 2004)
" We report a case of a 71-year-old woman with type 2 diabetes on dapagliflozin, presenting with foul-smelling discharge and a large abscess in the perianal area."4.02Fournier's gangrene with dapagliflozin in a rural hospital: a case report. ( Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y, 2021)
"Seventy drug-naïve patients with type 2 diabetes (mean age, 52."3.30Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. ( Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M, 2023)
"In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin."2.74Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. ( Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M, 2009)
" A dosage of 70/30 insulin before supper was titrated, seeking fasting capillary blood glucose (FBG) 120 mg/dl (6."2.69Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. ( Riddle, MC; Schneider, J, 1998)
"15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide)."1.51Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. ( Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE, 2019)
"Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)."1.48Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018)
"Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes."1.39The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's4 (28.57)29.6817
2010's7 (50.00)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Lim, S1
Sohn, M1
Florez, JC1
Nauck, MA1
Ahn, J1
Elbeddini, A1
Tayefehchamani, Y1
Davey, M1
Gallinger, J1
Hooda, N1
Aly, A1
Erickson, D1
Lee, S1
Shao, N1
Yu, XY1
Yu, YM1
Li, BW1
Pan, J1
Wu, WH1
Zhang, HJ1
Ma, XF1
Hao, M1
Kuang, HY1
Savchenko, LG1
Digtiar, NI1
Selikhova, LG1
Kaidasheva, EI1
Shlykova, OA1
Vesnina, LE1
Kaidashev, IP1
El-Haggar, SM1
Farrag, WF1
Kotkata, FA1
Nauck, M1
Frid, A1
Hermansen, K1
Shah, NS1
Tankova, T1
Mitha, IH1
Zdravkovic, M2
Düring, M1
Matthews, DR1
Al-Jebawi, AF1
Lee, YH1
Lee, BW1
Chun, SW1
Cha, BS1
Lee, HC1
Horowitz, M1
Flint, A1
Jones, KL1
Hindsberger, C1
Rasmussen, MF1
Kapitza, C1
Doran, S1
Jax, T1
Chapman, IM1
Darsalia, V1
Ortsäter, H1
Olverling, A1
Darlöf, E1
Wolbert, P1
Nyström, T1
Klein, T1
Sjöholm, Å1
Patrone, C1
Mori, Y1
Komiya, H1
Kurokawa, N1
Tajima, N1
Shukla, UA1
Chi, EM1
Lehr, KH1
Inukai, K1
Watanabe, M1
Nakashima, Y1
Sawa, T1
Takata, N1
Tanaka, M1
Kashiwabara, H1
Yokota, K1
Suzuki, M1
Kurihara, S1
Awata, T1
Katayama, S1
Riddle, MC1
Schneider, J1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)[NCT05196958]20 participants (Anticipated)Interventional2022-01-25Recruiting
Chinese People's Liberation Army General Hospital[NCT02930265]400 participants (Anticipated)Interventional2016-09-30Enrolling by invitation
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With[NCT00318461]Phase 31,091 participants (Actual)Interventional2006-05-31Completed
Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients[NCT04529278]Phase 218 participants (Actual)Interventional2021-01-18Active, not recruiting
A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)[NCT03421119]Phase 3300 participants (Anticipated)Interventional2019-06-20Not yet recruiting
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.[NCT05419726]20 participants (Anticipated)Observational2023-02-01Recruiting
A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo[NCT01511692]Phase 143 participants (Actual)Interventional2005-11-30Completed
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From the Health Insurance Review and Assessment Service Database[NCT05817097]22,119 participants (Anticipated)Observational2023-08-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Beta-cell Function at Week 104

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 104

Interventionpercentage point (%point) (Least Squares Mean)
Lira 0.6 + Met64.48
Lira 1.2 + Met27.30
Lira 1.8 + Met17.81
Met Mono-7.89
Met + Glim11.25

Change in Beta-cell Function at Week 26

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 26

Interventionpercentage point (%point) (Least Squares Mean)
Lira 0.6 + Met20.45
Lira 1.2 + Met20.33
Lira 1.8 + Met26.12
Met Mono-1.63
Met + Glim24.68

Change in Body Weight at Week 104

Change in body weight from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104

Interventionkg (Least Squares Mean)
Lira 0.6 + Met-2.07
Lira 1.2 + Met-3.03
Lira 1.8 + Met-2.91
Met Mono-1.80
Met + Glim0.70

Change in Body Weight at Week 26

Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

Interventionkg (Least Squares Mean)
Lira 0.6 + Met-1.78
Lira 1.2 + Met-2.58
Lira 1.8 + Met-2.79
Met Mono-1.51
Met + Glim0.95

Change in Fasting Plasma Glucose (FPG) at Week 104

Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-0.80
Lira 1.2 + Met-1.20
Lira 1.8 + Met-1.18
Met Mono0.75
Met + Glim-0.64

Change in Fasting Plasma Glucose (FPG) at Week 26

Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.13
Lira 1.2 + Met-1.63
Lira 1.8 + Met-1.68
Met Mono0.40
Met + Glim-1.31

Change in Glycosylated A1c (HbA1c) at Week 104

Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 104

Interventionpercentage of total haemoglobin (Least Squares Mean)
Lira 0.6 + Met-0.36
Lira 1.2 + Met-0.56
Lira 1.8 + Met-0.58
Met Mono0.25
Met + Glim-0.50

Change in Glycosylated A1c (HbA1c) at Week 26

Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 0.6 + Met-0.69
Lira 1.2 + Met-0.97
Lira 1.8 + Met-1.00
Met Mono0.09
Met + Glim-0.98

Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104

Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.59
Lira 1.2 + Met-2.22
Lira 1.8 + Met-2.10
Met Mono-0.43
Met + Glim-1.80

Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26

Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.68
Lira 1.2 + Met-2.33
Lira 1.8 + Met-2.57
Met Mono-0.62
Met + Glim-2.46

Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104

"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-0.27
Lira 1.2 + Met-0.56
Lira 1.8 + Met-0.44
Met Mono-0.20
Met + Glim-0.29

Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26

"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/l (Least Squares Mean)
Lira 0.6 + Met-0.23
Lira 1.2 + Met-0.40
Lira 1.8 + Met-0.56
Met Mono-0.44
Met + Glim-0.44

Hypoglycaemic Episodes at Week 104

Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-104

,,,,
Interventionepisodes (Number)
AllMajorMinorSymptoms only
Lira 0.6 + Met5202329
Lira 1.2 + Met5112624
Lira 1.8 + Met4902227
Met + Glim5240284240
Met Mono180612

Hypoglycaemic Episodes at Week 26

Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-26

,,,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Lira 0.6 + Met01517
Lira 1.2 + Met037
Lira 1.8 + Met0922
Met + Glim0136175
Met Mono0610

Trials

8 trials available for glimepiride and Obesity

ArticleYear
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
    Nutrients, 2023, Jan-03, Volume: 15, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastrointestinal Microbiome; Gl

2023
Effect of ketotifen in obese patients with type 2 diabetes mellitus.
    Journal of diabetes and its complications, 2015, Volume: 29, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Huma

2015
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure.
    International journal of clinical practice, 2011, Volume: 65, Issue:10

    Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glyca

2011
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female;

2004
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
    Diabetes research and clinical practice, 2005, Volume: 68, Issue:3

    Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe

2005
Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Diabetes care, 1998, Volume: 21, Issue:7

    Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Diabetes Mell

1998

Other Studies

6 other studies available for glimepiride and Obesity

ArticleYear
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
    BMJ case reports, 2021, Feb-01, Volume: 14, Issue:2

    Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes

2021
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
    Andrologia, 2018, Volume: 50, Issue:7

    Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Com

2018
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2019, Sep-01, Volume: 57, Issue:3

    Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression

2019
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
    Diabetes research and clinical practice, 2010, Volume: 90, Issue:3

    Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Rem

2010
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
    Diabetes, 2013, Volume: 62, Issue:4

    Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglyc

2013
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
    Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:1

    Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type

2004